Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35

A News Letter Sign UP!
EVALUATION OF SOME GENERIC DRUGS FOR REVERSAL OF MULTIDRUG-RESISTANCE IN PSEUDOMONAS AERUGINOSA USING COMPUTER-AIDED DRUG DESIGN

Research Paper Open Access

International Journal of Latest Research in Science and Technology Vol.6 Issue 5, pp 60-66,Year 2017

EVALUATION OF SOME GENERIC DRUGS FOR REVERSAL OF MULTIDRUG-RESISTANCE IN PSEUDOMONAS AERUGINOSA USING COMPUTER-AIDED DRUG DESIGN

Adamu, Ahmed Adamu,Bello, shaibu Oricha,Chika, Aminu

Correspondence should be addressed to :

Received : 20 October 2017; Accepted : 28 October 2017 ; Published : 14 November 2017

Share
Download 125
View 183
Article No. 10760
Abstract

The alarming rate of the increase in multidrug-resistant cases of Pseudomonas aeruginosa is a growing clinical issue necessitating the urgent need for new antibiotics and alternative strategies to combat the bacterial pathogen. Repurposing approved drugs in clinical use with known pharmacology and toxicology is one such cost-effective alternative approach. In this study, four essential protein targents for P. aeruginosa involved in the development of multidrug resistance were selected from Protein Data Bank using a validated method. Structure-based virtual screening method with PyRx was used to screen a database of 175 approved drugs. Celecoxib and meloxicam (marketed inhibitors of cyclooxygenase-2), fluconazole (an antifungal), desloratadine (antihistamine) and nitrofurantoin were found to bind with all the protein targets with binding energy greater than that obtained with the respective cocrystallized ligands.

Key Words   
P. aeruginosa,PyRx,multidrug-resistant, Molecular

Copyright
References
  1. So, A.D., et al., 3Rs for Innovating Novel Antibiotics: Sharing Resources, Risks, and Rewards. British Medical Journal, 2012. 344(3): p. e1782.
  2. Davies, J. and D. Davies, Origins and Evolution of Antibiotic Resistance. Microbiology and Molecular Biology Reviews, 2010. 74(3): p. 417-433.
  3. Aminov, R.I., A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future. Frontiers in Microbiology, 2010. 1.
  4. Martínez, J.L., F. Baquero, and D.I. Andersson, Predicting Antibiotic Resistance. Nature Reviews Microbiology, 2007. 5(12): p. 958-965.
  5. Riou, M., et al., Prevalence and Epidemiology of Antibiotic Resistance in Pseudomonas aeruginosa Isolated from Lower Respiratory Tract of Patients Hospitalized in Intensive Care Units (ICU) from 5 Belgian Hospitals during the 2004-2008 Period., in 19th ECCMID Helsinki Finland. 2009.
  6. Jean, S. and P. Hsuh, High Burden of Antimicrobial Resistance in Asia. International Journal of Antimicrobial Agents., 2011. 37(4): p. 291-295.
  7. Garba, I., et al., Antibiotics Susceptibility Pattern of Pseudomonas aeruginosa Isolated from Wounds in Patients Attending Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. Nigerian Journal of Basic and Applied Science, 2012: p. 32-34.
  8. Akingbade, O.A., et al., Plasmid Profile Analysis of Multidrug Resistant Pseudomonas aeruginosa Isolated from Wound Infections in South West, Nigeria. World AppliedSciences Journal 20 (6): p. 766-775.
  9. CDC, Antibiotic Resistance Treats in the United State. . 2013, Center for Disease Control and Prevention.
  10. Nakamura, A., et al., Meropenem as Predictive Risk Factor for Isolation of Multidrug-Resistant Pseudomonas aeruginosa. Journal of Hospital Infection., 2013. 83(2): p. 153-155.
  11. Li, J., R.L. Nation, and J.D. Turnidge, Colistin: The Re-emerging Antibiotic for Multidrug-Resistant Gram-Negative Bacterial Infections. . Lancet Infectious Disease. , 2006. 6(9): p. 589-601.
  12. IDSA, Antimicrobial (Drug) Resistance, N.I.A.a.I. Diseases, Editor. 2009, USA Gov.
  13. Yuan, Z. and V.H. Tam, Polymyxin B: A New Strategy for Multidrug-Resistant Gram-Negative Organisms. . Expert Opin. Investig. Drugs 2008. 17(5): p. 661-668.
  14. Paul, S.M., et al., How to Improve R&D Rroductivity: The Pharmaceutical Industry's Grand Challenge. Nature Reviews Drug Discovery, 2010. 9(3): p. 203-214.
  15. Tan, S.Y.-Y., et al., Identification of Five Structurally Unrelated Quorum-sensing Inhibitors of Pseudomonas aeruginosa from a Natural-derivative Database. Antimicrobial Agents and Chemotherapy, 2013. 57(11): p. 5629-5641.
  16. Hansen, M.R., et al., Solid‐Phase Synthesis and Biological Evaluation of N‐Dipeptido L‐Homoserine Lactones as Quorum Sensing Activators. ChemBioChem, 2014. 15(3): p. 460-465.
  17. Zeng, Z., et al., Virtual Screening for Novel Quorum sensing Inhibitors to Eradicate Biofilm Formation of Pseudomonas aeruginosa. Applied Microbiology and Biotechnology, 2008. 79(1): p. 119-126.
  18. Farmer, R., et al., Virtual Screening of AmpC/β‐lactamase as Target for Antimicrobial Resistance in Pseudomonas aeruginosa. Bioinformation, 2010. 4(7): p. 290.
  19. Taylor, P.L., et al., Structure and Function of Sedoheptulose-7-Phosphate Isomerase, a Critical Enzyme for Lipopolysaccharide Biosynthesis and a Target for Antibiotic Adjuvants. J Biol Chem, 2008. 283(5): p. 2835-45.
  20. Hiraiwa, Y., et al., X-ray Crystallographic Analysis of IMP-1 Metallo-beta-lactamase Complexed with a 3-aminophthalic acid Derivative, Structure-based Drug Design, and Synthesis of 3,6-disubstituted phthalic acid Derivative iInhibitors. Bioorg Med Chem Lett, 2014. 24(20): p. 4891-4.
  21. Warren, G.L., et al., Essential Considerations for Using Protein–Ligand Structures in Drug Discovery. Drug Discovery Today, 2012. 17(23): p. 1270-1281.
  22. Yunusa, A., S.O. Bello, and A. Chika, Computational Drug Re-Positioning: An Approach to Discover Novel Antimalarials IJLRST, 2015. 4(4): p. 119-127.
  23. Law, V., et al., DrugBank 4.0: Shedding New Light on Drug Metabolism. Nucleic acids Research, 2014. 42(D1): p. 1091-D1097.
  24. Matter, H., Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-dimensional and Three-dimensional Molecular Descriptors. Journal of Medicinal Chemistry, 1997. 40(8): p. 1219-1229.
  25. Usha, T., et al., Identification of Anti-Cancer Targets of Eco-Friendly Waste Punica granatum Peel by Dual Reverse Virtual Screening and Binding Analysis. Asian Pacific Journal of Cancer Prevention, 2014. 15(23): p. 10345.
  26. Bhattacharjee, B. and J. Chatterjee, Identification of Proapoptopic, Anti-inflammatory, Anti-proliferative, Anti-invasive and Anti-angiogenic Targets of Essential Oils in Cardamom by Dual Reverse Virtual Screening and Binding Pose Analysis. Asian Pacific Journal of Cancer Prevention, 2013. 14(6): p. 3735-3742.
  27. Chen, S., A Potential Target of Tanshinone IIA for Acute Promyelocytic Leukemia Revealed by Inverse Docking and Drug Repurposing. Asian Pacific journal of cancer prevention: APJCP, 2014. 15(10): p. 4301.
  28. Thangamani, S., W. Younis, and M.N. Seleem, Repurposing celecoxib as a topical antimicrobial agent. Front Microbiol, 2015. 6: p. 750.
  29. Kalle, A.M. and A. Rizvi, Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother, 2011. 55(1): p. 439-42.
  30. Soheili, V., et al., Investigation of Pseudomonas aeruginosa quorum-sensing signaling system for identifying multiple inhibitors using molecular docking and structural analysis methodology. Microbial Pathogenesis, 2015. 89: p. 73-78.
  31. Cunha, B.A., Nitrofurantoin current concepts. Urology, 1988. 32(1): p. 67-71.
  32. Grayson, M. and M. Whitby, Nitrofurans: nitrofurazone, furazolidone and nitrofurantoin. Kucers’ The Use of Antibiotics, Sixth Edition. London: Hodder Arnold, 2010: p. 1195-204.
To cite this article

Adamu, Ahmed Adamu,Bello, shaibu Oricha,Chika, Aminu , " Evaluation Of Some Generic Drugs For Reversal Of Multidrug-resistance In Pseudomonas Aeruginosa Using Computer-aided Drug Design ", International Journal of Latest Research in Science and Technology . Vol. 6, Issue 5, pp 60-66 , 2017

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.